EICHORPublic-registry site landscape for NCT07754786, “A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic Dermatitis”, a Atopic Dermatitis study sponsored by Innovent Biologics (Suzhou) Co. Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07754786 (registry record) |
| Study title | A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic Dermatitis |
| Official title | A Multicenter, Randomized, Double-blind, Parallel, and Positive-controlled Phase III Clinical Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic Dermatitis |
| Sponsor | Innovent Biologics (Suzhou) Co. Ltd. |
| Condition(s) | Atopic Dermatitis |
| Phase | PHASE3 |
| Listed sites | 1 |
| Intervention(s) | Dupilumab Injection, IBI3027 |
| Site countries | China |
At Southern Medical University Dermatology Hospital Medicine — one of the facilities listed on this trial — 4 other studies are actively recruiting Atopic Dermatitis patients at the same facility (public registry, as of August 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Patient-friendly overview of this study: eichor.com/study/NCT07754786.
Eichor generates a preliminary site-risk snapshot for NCT07754786 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Atopic Dermatitis trials
More from Innovent Biologics (Suzhou) Co. Ltd.
← Eichor home · All tracked trials · Atopic Dermatitis studies · Weekly briefs
